Biotech Values

[DewDiligence]

DVAX—The n=9 cohort that was PD-(L)1-naïve doesn’t tell us much insofar as the responses could have been due entirely to Keytruda. So, let’s look at the n=12 (excluding the “non-evaluable” patient) cohort that previously progressed on PD-(L)1 therapy; in this cohort, 2 of the 12 patients (one of whom had a PR) had not yet had disease progression (or death) after 10.5 months, while the other 10 patients had disease progression after 1.5-8 months.

It would be helpful to know the PD-L1 and TMB status of these patients; absent that, I would say the above results are modestly impressive, but no better than that.